Immunovant FY2025 EPS Estimate Raised by Leerink Partnrs

Immunovant, Inc. (NASDAQ:IMVT) – Investment analysts at Leerink Partnrs boosted their FY2025 EPS estimates for Immunovant in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($2.88) per share for the year, up from their prior forecast of ($2.92). The consensus estimate for Immunovant’s current full-year earnings is ($2.74) per share. Leerink Partnrs also issued estimates for Immunovant’s Q4 2025 earnings at ($0.75) EPS, FY2026 earnings at ($2.85) EPS, FY2027 earnings at ($2.68) EPS, FY2028 earnings at ($2.27) EPS and FY2029 earnings at ($1.34) EPS.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.08).

Several other brokerages have also issued reports on IMVT. Guggenheim decreased their price target on Immunovant from $46.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday. Wolfe Research cut Immunovant from an “outperform” rating to a “peer perform” rating in a research report on Friday, January 3rd. HC Wainwright reissued a “buy” rating and issued a $51.00 target price on shares of Immunovant in a report on Friday. Bank of America decreased their price target on shares of Immunovant from $48.00 to $45.00 and set a “buy” rating on the stock in a report on Wednesday, January 15th. Finally, Cantor Fitzgerald upgraded shares of Immunovant to a “strong-buy” rating in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $46.73.

Immunovant Price Performance

Shares of IMVT opened at $19.52 on Monday. The firm has a 50 day simple moving average of $24.75 and a two-hundred day simple moving average of $27.79. The company has a market cap of $3.32 billion, a P/E ratio of -7.45 and a beta of 0.65. Immunovant has a one year low of $19.09 and a one year high of $39.55.

Institutional Investors Weigh In On Immunovant

Large investors have recently modified their holdings of the company. FMR LLC lifted its holdings in Immunovant by 19.6% in the third quarter. FMR LLC now owns 12,537,571 shares of the company’s stock valued at $357,446,000 after buying an additional 2,053,688 shares during the period. Baker BROS. Advisors LP lifted its stake in shares of Immunovant by 163.7% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,225,410 shares of the company’s stock valued at $34,936,000 after purchasing an additional 760,692 shares during the period. Principal Financial Group Inc. boosted its position in shares of Immunovant by 69.9% during the 3rd quarter. Principal Financial Group Inc. now owns 951,124 shares of the company’s stock valued at $27,117,000 after purchasing an additional 391,436 shares in the last quarter. State Street Corp grew its stake in Immunovant by 11.2% during the third quarter. State Street Corp now owns 3,022,342 shares of the company’s stock worth $86,167,000 after purchasing an additional 303,386 shares during the period. Finally, Geode Capital Management LLC grew its stake in Immunovant by 6.9% during the third quarter. Geode Capital Management LLC now owns 1,510,926 shares of the company’s stock worth $43,085,000 after purchasing an additional 96,924 shares during the period. 47.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CTO Jay S. Stout sold 2,195 shares of the stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $23.59, for a total value of $51,780.05. Following the completion of the sale, the chief technology officer now owns 139,991 shares of the company’s stock, valued at approximately $3,302,387.69. This represents a 1.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Eva Renee Barnett sold 4,174 shares of Immunovant stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $25.45, for a total value of $106,228.30. Following the completion of the transaction, the chief financial officer now directly owns 331,169 shares in the company, valued at approximately $8,428,251.05. This represents a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,892 shares of company stock valued at $1,811,857. Insiders own 5.90% of the company’s stock.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.